Teacher Retirement System of Texas Grows Holdings in Hologic, Inc. (NASDAQ:HOLX)

Teacher Retirement System of Texas raised its position in Hologic, Inc. (NASDAQ:HOLX) by 82.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 649,883 shares of the medical equipment provider’s stock after buying an additional 294,538 shares during the period. Teacher Retirement System of Texas’ holdings in Hologic were worth $46,850,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swedbank AB lifted its holdings in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares during the period. GSA Capital Partners LLP lifted its holdings in shares of Hologic by 22.2% during the 3rd quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock worth $469,000 after acquiring an additional 1,048 shares during the period. OneDigital Investment Advisors LLC lifted its holdings in shares of Hologic by 5.4% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider’s stock worth $576,000 after acquiring an additional 360 shares during the period. Empowered Funds LLC lifted its holdings in shares of Hologic by 8.8% during the 3rd quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider’s stock worth $294,000 after acquiring an additional 291 shares during the period. Finally, Pathstone Holdings LLC lifted its holdings in shares of Hologic by 7.7% during the 3rd quarter. Pathstone Holdings LLC now owns 29,731 shares of the medical equipment provider’s stock worth $2,422,000 after acquiring an additional 2,121 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Stephens reissued an “overweight” rating and set a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Down 0.7 %

Shares of NASDAQ:HOLX opened at $61.01 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The company has a 50 day moving average of $66.26 and a two-hundred day moving average of $74.19. The company has a market capitalization of $13.69 billion, a price-to-earnings ratio of 19.25, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.